DIABETON MB IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS AND PREVENTION OF ITS LATE COMPLICATIONS


Cite item

Full Text

Abstract

The article is dedicated to the role of sulfonylureas (SU), primarily gliclazide (Diabeton MR) in the treatment of type 2 diabetes mellitus (DM2), discusses their effects on the cardiovascular system. Data supporting the benefits of gliclazide in front of so-called old SU (glibenclamide, etc.) are presented. It is shown that in addition to pronounced hypoglycemic action gliclazide has an antioxidant property, ability to prevent development of micro- and macrovascular complications of DM2, including myocardial infarction and stroke. The antioxidant properties, the lack of effect on apoptosis provide gentle action of this drug on β-cells, that is also a undeniable advantage of gliclazide.

References

  1. Guillasseau PJ, Greb W. 24-hour glycemic profile in type 2 diabetic patient treated with gliclazide modified realease once daily. Diabete Metab 2001;27:133-37.
  2. Salas M, Caro JJ. Are hypoglycemia and other adverse effects similar among sulphonylureas. Advers Drug React Toxicol Rev 2002;21:205-17.
  3. Drouin P. Diamicron MR study group. J Diabet Complic 2000;14:185-91.
  4. The ADVANCE collaborative group. N Engl J Med 2008;358:2560-72.
  5. Schernthaner G, Di Mario U, Grimaldi A. Glucose control in type 2 diabetes. Diamicron MR versus glimeprirde. Diabetologia 2003;45(suppl. 2):A281.
  6. Ashcroft FM, Gribble FM. Sulfonilurea stimulation of insulin secretion: lessons from studies of cloned channels. J Diabet Compl 2000;12:2182-8.
  7. Seino S, Miki T. КATP channels as metabolitic sensors: protective roles against acute metabolic changes. Medicographia 2005;27(4):3007-10.
  8. Pogatsa G, et al. Effects of Glimepiride and Gliclazide on Cardiac Arrhytmias in Patient with type 2 diabetes and cardiac insufficiency. Diabetes 2001;50(suppl.):A128.
  9. Maddock HL, Siedlecka SM, Yellon DM. Myocardial protection from either ischemic preconditioning or nicorandil is not blocked by gliclazide. Cardiovasc Drugs Ther 2004;18:113-19.
  10. Gribble FM, Tuccker SJ, Seino S, Ashcroft FM. Tissue specifity of sulfonilureas: studies on cloned cardiac and β-cell KATP channels. Diabetes 1998;47:1412-18.
  11. Ashcroft FM, Gribble FM. ATP sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia 1999;42:903-19.
  12. O'Brien RC, Luo M, Balazs N, Mercuri J. In-vitro and in-vivo antioxidant properties of gliclazide. J Diabet Complic 2000;14:201-06.
  13. Fava D, Cassone-Faldetta M, et al. Gliclazide improves antioxidant status and nitric oxide-mediated vasodilatation in type 2 diabetes. Diabetic Med 2002;19:752-3.
  14. Alvarsson M, Sundkvista G, et al. Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 DM. Diabetes Care 2003;26:2331-37.
  15. Robertson RP. Chronic oxidative stress as a central mechanism for glucose toxicity in pancreatic islet beta cells in diabetes. J Biol Chem 2004;279:42351-54.
  16. Iwakura T, Fujimoto S, et al. Sustained enhancement of Ca2+ influx by glibenclamide induces apoptosis in RINm5F cells. Biochem Biophys Res Commun 2000;271:422-28.
  17. Kimoto K, Suzuki K, et al. Cliclazide protects pancreatic β-cells from damage by hydrogen peroxide. Biochem Biophys Res Commun 2003;303:112-19.
  18. Noda Y, Mori A, et al. Cliclazide scavenges hydroxyl and superoxide radicals: an electron spin resonance study. Metabolism 2000;49(suppl.):14-26.
  19. Satoh J, Takahashi K. Secondary sulfonylurea failure. Diabet Res Clin Pract 2005;70:291-97.
  20. Florkowski CM, Richardson MR, Le Guen C, et al. Effect of gliclazide on parameters of hemostasis, lipid thromboxane B2 peroxides and fluorescent IgG in type 2 diabetes mellitus. Diabetologia 1988;31:490A.
  21. Johnsen SP, Monster TBM, Olsen ML, et al. Risk and short-term prognosis of myocardial infarction among users of antidiabetic drugs. Am J Ther 2006;13(2):134-40.
  22. Schramm TK, Gislason GH, Vaag A, et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study. Eur Heart J 2011;doi: 10.1093/eurheartj/ehr077.
  23. Khalangot M, Tronko M, Kravchenko V, Kovtun V. Glibenclamide-related excess in total and ardiovascular mortality risks: data from large Ukrainian observational cohort study. Diabet Res Clin Pract 2009;86:247-53.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2011 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies